205 related articles for article (PubMed ID: 25735362)
1. Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus.
Wang JN; Xu LH; Zeng WG; Hu P; Rabkin SD; Liu RR
Asian Pac J Cancer Prev; 2015; 16(3):1241-5. PubMed ID: 25735362
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.
Wang JN; Hu P; Zeng MS; Liu RB
Chin J Cancer; 2011 Dec; 30(12):831-41. PubMed ID: 22059912
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
4. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
5. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta.
Wang J; Xu L; Zeng W; Hu P; Zeng M; Rabkin SD; Liu R
Cancer Cell Int; 2014; 14(1):83. PubMed ID: 25360068
[TBL] [Abstract][Full Text] [Related]
6. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.
Nigim F; Esaki S; Hood M; Lelic N; James MF; Ramesh V; Stemmer-Rachamimov A; Cahill DP; Brastianos PK; Rabkin SD; Martuza RL; Wakimoto H
Neuro Oncol; 2016 Sep; 18(9):1278-87. PubMed ID: 26951380
[TBL] [Abstract][Full Text] [Related]
7. Treatment of aggressive thyroid cancer with an oncolytic herpes virus.
Yu Z; Eisenberg DP; Singh B; Shah JP; Fong Y; Wong RJ
Int J Cancer; 2004 Nov; 112(3):525-32. PubMed ID: 15382081
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
9. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
Antoszczyk S; Spyra M; Mautner VF; Kurtz A; Stemmer-Rachamimov AO; Martuza RL; Rabkin SD
Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.
Liu RB; Rabkin SD
Chin Med J (Engl); 2005 Feb; 118(4):307-12. PubMed ID: 15740669
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo.
Nagayama Y; Yokoi H; Takeda K; Hasegawa M; Nishihara E; Namba H; Yamashita S; Niwa M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4081-6. PubMed ID: 11095436
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein.
Shi Y; Parhar RS; Zou M; Baitei E; Kessie G; Farid NR; Alzahrani A; Al-Mohanna FA
Hum Gene Ther; 2003 Dec; 14(18):1741-51. PubMed ID: 14670125
[TBL] [Abstract][Full Text] [Related]
13. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo.
Nishihara E; Nagayama Y; Mawatari F; Tanaka K; Namba H; Niwa M; Yamashita S
Endocrinology; 1997 Nov; 138(11):4577-83. PubMed ID: 9348181
[TBL] [Abstract][Full Text] [Related]
14. Treatment of breast cancer stem cells with oncolytic herpes simplex virus.
Li J; Zeng W; Huang Y; Zhang Q; Hu P; Rabkin SD; Liu R
Cancer Gene Ther; 2012 Oct; 19(10):707-14. PubMed ID: 22898897
[TBL] [Abstract][Full Text] [Related]
15. The oncolytic herpes simplex virus vector, G47Δ, effectively targets tamoxifen-resistant breast cancer cells.
Fan J; Jiang H; Cheng L; Liu R
Oncol Rep; 2016 Mar; 35(3):1741-9. PubMed ID: 26718317
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
17. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.
Liu R; Varghese S; Rabkin SD
Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042
[TBL] [Abstract][Full Text] [Related]
19. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
20. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
